Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus


OBJECTIVES: To study associations between antinuclear antibodies (ANA) and signs/symptoms in patients with systemic lupus erythematosus (SLE).

METHODS: A consecutive cohort of 289 patients with SLE was included: 235 fulfilled ACR criteria for SLE and were further analysed. ANA profiles were determined by line immunoassay and by indirect immunofluorescence on Crithidia luciliae. An extensive list of signs/symptoms was evaluated.

RESULTS: Five clusters of antibodies were defined by cluster analysis: 1—antibodies to SmB, SmD, RNP-A, RNP-C, and RNP-70k; 2—antibodies to Ro52, Ro60, and SS-B; 3, 4, and 5—antibodies to ribosomal P, histones and dsDNA, respectively. Significant associations (p ≤ 0.01) were found between anti-RNP-70k, anti-RNP-A, anti-RNP-C and Raynaud’s phenomenon, between anti-RNP-A, anti-RNP-70k and leucopenia, and between anti-RNP-A, anti-RNP-C and a lower prevalence of urine cellular casts. Anti-SS-A, anti-SS-B were associated with xerostomia, and anti-SS-B with pericarditis. Antibodies to ribosomal P were associated with haemolytic anaemia, leucopenia, and alopecia. Patients with anti-dsDNA antibodies had a higher risk for cellular casts and a lower risk for photosensitivity. Antihistone antibodies were associated with arthritis.

CONCLUSIONS: In a large and consecutive cohort of patients with SLE, clusters of antibodies were identified. Previously reported associations of antibodies with symptoms were confirmed and new associations found.

The presence of autoantibodies is important for the diagnosis of systemic lupus erythematosus (SLE). Antinuclear antibodies (ANA), anti-Sm, or anti-dsDNA antibodies are part of the American College of Rheumatology criteria for SLE.1,2 Specific reactivities are associated with distinct clinical features of SLE.3–5 Known associations are anti-dsDNA antibodies with lupus nephritis,4,5 anti-SS-A and anti-SS-B antibodies with sicca symptoms,6–8 and anti-RNP antibodies with Raynaud’s phenomenon.9,10 More associations have been described, but different studies yield conflicting results.11–13

Earlier studies used counterimmunoelectrophoresis or immunodiffusion for the detection of specific ANA, but more sensitive techniques have now been developed—for instance, a line immunoassay (LIA).14–16 We designed this study to evaluate associations of specific ANA detected by LIA, and anti-dsDNA detected by indirect immunofluorescence (IIF) on Crithidia luciliae, and symptoms of SLE in a consecutive cohort of patients.

PATIENTS AND METHODS

Patients

Two hundred and eighty-nine patients diagnosed as having SLE, were prospectively included in four European centres (University Hospital Ghent, Belgium; University Hospital Leiden, The Netherlands; Research Institute for Rheumatic Diseases Piestany, Slovakia; University College London, United Kingdom). Of these patients, 235 (81.3%) met the ACR revised criteria for classification of SLE,12 and were further analysed. The male to female ratio was 29:206. The mean age was 40 years (range 16–77).

A questionnaire covering the clinical data was completed, based on anamnesis and available medical data. Data were listed as present among the past year or earlier during the disease. The questionnaire was an extension of the ACR criteria for SLE (table 1). The study was conducted after approval by the local ethics committees. Informed consent was obtained from all patients.

ANA

The results obtained in each centre at the time of sampling were used. All centres used IIF on HEp-2 or HEp-2000 cells.

LIA

Serum samples were analysed in a single laboratory by LIA (INNO-LIA ANA Update, Innogenetics NV, Zwijnaarde, Belgium) as described previously.7 This assay contains the following recombinant and natural antigens: SmB, SmD, RNP-A, RNP-C, RNP-70k, Ro52, Ro60, La/SSB, Cenp-B, Topo-I, Jo-1, ribosomal P, and histones.

Anti-dsDNA antibodies

Anti-dsDNA antibodies were detected by IIF on Crithidia luciliae (Immunoconcepts, Sacramento, USA). Samples were analysed in a single laboratory.

Statistical analysis

Statistical analysis was performed using SPSS (Chicago, IL, USA). We performed cluster analysis using average linkage (between groups), based on the squared Euclidean distance. This is a hierarchical clustering method, aiming to group similar variables together. To determine associations between autoantibodies and symptoms, χ² or Fisher’s exact tests were used. We computed odds ratios (OR) and their 95% confidence interval (95% CI). No correction for multiple testing was made, but only a p value ≤ 0.01 was taken to indicate significance.

RESULTS

Presence of ANA

ANA were found by IIF in 280/291 (96.2%) patients. The frequencies of the specific reactivities were: anti-Ro52 or anti-Ro60 31.5%; anti-dsDNA 29.1%; anti-Ro60 28.9%; antihistones 28.5%; anti-SmB 28.1%; anti-RNP-C 24.3%.

Abbreviations: ANA, antinuclear antibodies; IIF, indirect immunofluorescence; LIA, line immunoassay; SLE, systemic lupus erythematosus
Table 1  Prevalence of the different symptoms during the year before sampling and during the entire course of the disease

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Prevalence past year (%)</th>
<th>Frequency ever (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cutaneous symptoms</td>
<td>74.2</td>
<td>93.3</td>
</tr>
<tr>
<td>Butterfly rash</td>
<td>33.0</td>
<td>68.0</td>
</tr>
<tr>
<td>Photosensitivity</td>
<td>29.3</td>
<td>60.7</td>
</tr>
<tr>
<td>Alopecia</td>
<td>27.2</td>
<td>57.1</td>
</tr>
<tr>
<td>Oral ulcers</td>
<td>13.3</td>
<td>30.6</td>
</tr>
<tr>
<td>Localised discoid rash</td>
<td>10.6</td>
<td>26.1</td>
</tr>
<tr>
<td>Disseminated discoid rash</td>
<td>6.4</td>
<td>13.7</td>
</tr>
<tr>
<td>Generalised erythema</td>
<td>4.3</td>
<td>13.7</td>
</tr>
<tr>
<td>Genital ulcers</td>
<td>4.3</td>
<td>6.3</td>
</tr>
<tr>
<td>Subacute cutaneous LE</td>
<td>2.6</td>
<td>3.4</td>
</tr>
<tr>
<td>Chilblains</td>
<td>1.3</td>
<td>1.3</td>
</tr>
<tr>
<td>Lupus profundus</td>
<td>0.7</td>
<td>1.4</td>
</tr>
<tr>
<td>Sicca</td>
<td>25.0</td>
<td>28.0</td>
</tr>
<tr>
<td>Xerostomia</td>
<td>22.2</td>
<td>25.6</td>
</tr>
<tr>
<td>Xerophthalmia</td>
<td>19.8</td>
<td>22.7</td>
</tr>
<tr>
<td>General symptoms</td>
<td>76.3</td>
<td>92.3</td>
</tr>
<tr>
<td>Fatigue</td>
<td>67.0</td>
<td>85.5</td>
</tr>
<tr>
<td>Raynaud’s phenomenon</td>
<td>40.3</td>
<td>47.8</td>
</tr>
<tr>
<td>Fever</td>
<td>16.7</td>
<td>66.2</td>
</tr>
<tr>
<td>Musculoskeletal symptoms</td>
<td>74.4</td>
<td>97.0</td>
</tr>
<tr>
<td>Arthritis</td>
<td>69.1</td>
<td>91.7</td>
</tr>
<tr>
<td>Arthritis</td>
<td>36.4</td>
<td>76.4</td>
</tr>
<tr>
<td>Myalgia</td>
<td>36.3</td>
<td>54.1</td>
</tr>
<tr>
<td>Serositis</td>
<td>16.9</td>
<td>47.9</td>
</tr>
<tr>
<td>Pleuritis</td>
<td>12.1</td>
<td>39.2</td>
</tr>
<tr>
<td>Péricarditis</td>
<td>5.8</td>
<td>24.9</td>
</tr>
<tr>
<td>Renal symptoms</td>
<td>32.4</td>
<td>58.9</td>
</tr>
<tr>
<td>Proteinuria</td>
<td>29.7</td>
<td>57.2</td>
</tr>
<tr>
<td>Glomerulonephritis*</td>
<td>21.8</td>
<td>48.3</td>
</tr>
<tr>
<td>Cellular casts</td>
<td>15.6</td>
<td>45.1</td>
</tr>
<tr>
<td>Neurological symptoms</td>
<td>39.8</td>
<td>60.1</td>
</tr>
<tr>
<td>Headache</td>
<td>23.4</td>
<td>37.6</td>
</tr>
<tr>
<td>Concentration disorder</td>
<td>17.6</td>
<td>25.0</td>
</tr>
<tr>
<td>Depression</td>
<td>12.4</td>
<td>20.1</td>
</tr>
<tr>
<td>Encephalopathy</td>
<td>5.5</td>
<td>9.3</td>
</tr>
<tr>
<td>Seizures</td>
<td>5.4</td>
<td>12.7</td>
</tr>
<tr>
<td>Cerebrovascular accident</td>
<td>2.4</td>
<td>10.2</td>
</tr>
<tr>
<td>Psychosis</td>
<td>2.4</td>
<td>7.9</td>
</tr>
<tr>
<td>Peripheral neuropathy</td>
<td>1.8</td>
<td>6.7</td>
</tr>
<tr>
<td>Cranial neuropathy</td>
<td>1.2</td>
<td>1.2</td>
</tr>
<tr>
<td>Transverse myelitis</td>
<td>0.6</td>
<td>1.9</td>
</tr>
<tr>
<td>Haematological symptoms</td>
<td>58.6</td>
<td>84.3</td>
</tr>
<tr>
<td>Lymphopenia</td>
<td>41.7</td>
<td>65.9</td>
</tr>
<tr>
<td>Leucopenia</td>
<td>34.5</td>
<td>67.0</td>
</tr>
<tr>
<td>Thrombopenia</td>
<td>11.7</td>
<td>36.2</td>
</tr>
<tr>
<td>Haemolytic anaemia</td>
<td>8.6</td>
<td>22.6</td>
</tr>
<tr>
<td>Thrombosis</td>
<td>3.0</td>
<td>13.2</td>
</tr>
<tr>
<td>Recurrent abortion</td>
<td>0</td>
<td>6.3</td>
</tr>
</tbody>
</table>

*Glamorulonephritis is defined as the occurrence of at least one of the following: ever proteinuria >1.5 g/24 h, or >30% decline in renal function or repeatedly active urine sediment, or uncontrolled hypertension, or biopsy proven glomerulonephritis.

Presence of clinical symptoms

Table 1 lists the frequencies of clinical symptoms. Only symptoms occurring in more than 10% of the patients during the past year and in more than 15% of the patients ever were analysed.

Identification of clusters of antibodies

Using cluster analysis, we identified five clusters of antibodies. Cluster 1 consisted of antibodies to SmB, SmD, RNP-A, RNP-C, and RNP-70k; cluster 2 consisted of antibodies to Ro52, Ro60, and SSB; clusters 3, 4, and 5 consisted of antibodies to ribosomal P, histones, and dsDNA, respectively (fig 1).

Associations of antibodies with symptoms

Table 2 lists the associations of antibodies with symptoms; corresponding OR and 95% CI are given. Only strong (p<0.001) associations are discussed here. At least one antibody of cluster 1 was found in 36.5% of the patients; such a pattern was associated with Raynaud’s phenomenon (past year or ever). The highest OR was found when anti-RNP-70k was present. At least one antibody of cluster 2 was found in 32.3% of the patients and this was associated with xerostomia ever. Furthermore, anti-RNP-A was associated with leucopenia past year, while anti-Ro52 was associated with haemolytic anaemia and alopecia past year.

DISCUSSION

The generation of autoantibodies is an important feature of SLE. Several studies have demonstrated that specific ANA are associated with different symptoms of SLE.3–5 10 In this study, we used a new multiparameter assay (LIA) for the detection of specific ANA. This is a more sensitive technique than immunodiffusion, and also allows for the detection of fine reactivities to the different determinants of Sm (SmB and SmD), RNP (RNP-A, RNP-C, and RNP-70k), and SSA (Ro52 and Ro60).7 9 It has already been suggested that autoantibody profiles might be a valuable alternative for individual autoantibodies. However, earlier studies used profiles generated only on the basis of pathophysiological considerations.3 Using cluster analysis, we defined five clusters of autoantibodies. Antibodies to the different determinants of the Sm/RNP system clustered together early. A second cluster was formed by Ro52, Ro60, and SSB, which is in accordance with studies using classical methods.10 11 The other clusters consisted of individual antibodies—namely, anti-ribosomal P, antihistone, and anti-dsDNA antibodies. The frequency of anti-dsDNA antibodies in our cohort is low compared with that in other studies.4 This may be explained by the cross sectional character of anti-RNP-A 20.4%; anti-Ro52 18.7%; reactivity with at least two RNP determinants 18.3%; anti-SSB 14.5%; anti-SmD 13.6%; anti-RNP-70k 13.2%; anti-ribosomal P 12.3%; anti-Cenp-B 2.6%; anti-Topo-I 2.6%; anti-Jo1 1.3%. Antibodies to Cenp-B, Topo-I, and Jo-1 were not considered further, because of their low frequencies.
our study: a consecutive cohort of patients with SLE seen at the participating clinics was included, regardless of disease activity or disease duration.

We then looked for associations of antibodies and clusters of antibodies with clinical signs/symptoms of SLE. Because we did not correct for multiple comparisons, the p values obtained should be interpreted with caution.

Previous studies found that anti-Sm antibodies were associated with oral ulcers, a lower prevalence of sicca symptoms, Raynaud’s phenomenon, thrombopenia, and leucopenia. We could not confirm these associations.

We confirmed the previously reported association between anti-RNP antibodies and Raynaud’s phenomenon (past year and ever). Also, significance was maintained when antibodies towards the individual RNP subparticles were considered. Consistent with earlier findings, we found an association between anti-RNP antibodies and arthritis (past year). Associations of renal disease with anti-RNP antibodies have been reported but remain controversial. In the present study, both anti-RNP-A and RNP-C antibodies were associated with a lower risk for urine cellular casts ever. Associations between antibodies to individual RNP subparticles and renal disease have not yet been reported. Other new associations concerning anti-RNP antibodies are the associations with fever and leucopenia during the past year and with malar rash ever. When considering the cluster Sm/RNP, patients with at least one antibody of the cluster had a higher risk for Raynaud’s phenomenon (past year and ever) and butterfly rash (ever).

We confirmed the well known associations of anti-SSA antibodies (defined as antibodies to Ro52 or Ro60) with xerostomia (past year and ever), but associations with xerophthalmia were not statistically significant. Looking at the individual antibodies we found a significant association between xerostomia and anti-Ro60 antibodies. We could not demonstrate the associations with subacute cutaneous lesions previously described. This is probably because of the low frequency of subacute cutaneous lesions in our patients. The association between anti-SSA and photosensitivity, which remains controversial, could not be confirmed. We confirmed the association between anti-SSB antibodies and xerostomia (past year and ever), while again the association with xerophthalmia was not significant. Consistent with earlier reports, we found an association between anti-SSB antibodies and pericarditis (past year). The presence of one of the three antibodies of the SSA/SSB cluster was associated with xerostomia (past year and ever), with xerophthalmia (ever), and with pericarditis (ever).

We confirmed associations of antiribosomal P antibodies and haematological disorders, more precisely with haemolytic anaemia (past year and ever) and leucopenia (past year). The association between antiribosomal P and alopecia (past year and ever) has not been described previously, and needs further confirmation. As psychosis was rare in our patients, we could not evaluate this association. Considering anti-histone antibodies, we found an association with arthritis (past year), which needs to be confirmed. Several studies have demonstrated an association between anti-dsDNA

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Associated symptom</th>
<th>OR</th>
<th>95% CI for OR</th>
</tr>
</thead>
<tbody>
<tr>
<td>RNP-70k</td>
<td>Raynaud’s phenomenon</td>
<td>19.5</td>
<td>4.4 to 86.2</td>
</tr>
<tr>
<td>RNP-70k</td>
<td>Raynaud’s phenomenon</td>
<td>15.3</td>
<td>3.5 to 67.1</td>
</tr>
<tr>
<td>Ribosomal P</td>
<td>Haemolytic anaemia</td>
<td>8.6</td>
<td>2.9 to 28.8</td>
</tr>
<tr>
<td>RNP-70k</td>
<td>Raynaud’s phenomenon</td>
<td>7.3</td>
<td>2.3 to 21.6</td>
</tr>
<tr>
<td>RNP-A</td>
<td>Raynaud’s phenomenon</td>
<td>7.0</td>
<td>3.1 to 15.8</td>
</tr>
<tr>
<td>At least 2 RNP reactivities</td>
<td>Raynaud’s phenomenon</td>
<td>5.6</td>
<td>2.4 to 12.7</td>
</tr>
<tr>
<td>At least 2 RNP reactivities</td>
<td>Raynaud’s phenomenon</td>
<td>5.0</td>
<td>2.1 to 11.2</td>
</tr>
<tr>
<td>Ribosomal P</td>
<td>Alopecia</td>
<td>4.4</td>
<td>1.7 to 11.2</td>
</tr>
<tr>
<td>At least 2 RNP reactivities</td>
<td>Fever</td>
<td>3.8</td>
<td>1.6 to 8.8</td>
</tr>
<tr>
<td>At least 1 antibody of cluster 1</td>
<td>Raynaud’s phenomenon</td>
<td>3.6</td>
<td>2.0 to 6.7</td>
</tr>
<tr>
<td>At least 1 antibody of cluster 2</td>
<td>Xerostomia</td>
<td>3.4</td>
<td>2.5 to 6.7</td>
</tr>
<tr>
<td>RNP-A</td>
<td>Leucopenia</td>
<td>3.2</td>
<td>1.9 to 6.5</td>
</tr>
<tr>
<td>At least 1 antibody of cluster 1</td>
<td>Raynaud’s phenomenon</td>
<td>2.8</td>
<td>1.5 to 5.0</td>
</tr>
</tbody>
</table>

p Value < 0.001

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Associated symptom</th>
<th>OR</th>
<th>95% CI for OR</th>
</tr>
</thead>
<tbody>
<tr>
<td>SSB</td>
<td>Pericarditis</td>
<td>7.1</td>
<td>1.9 to 26.7</td>
</tr>
<tr>
<td>Ribosomal P</td>
<td>Haemolytic anaemia</td>
<td>4.2</td>
<td>1.5 to 11.6</td>
</tr>
<tr>
<td>SSB</td>
<td>Xerostomia</td>
<td>4.0</td>
<td>1.6 to 10.0</td>
</tr>
<tr>
<td>SSB</td>
<td>Xerostomia</td>
<td>3.6</td>
<td>1.4 to 9.3</td>
</tr>
<tr>
<td>RNP-A</td>
<td>Arthralgia</td>
<td>3.4</td>
<td>1.4 to 8.6</td>
</tr>
<tr>
<td>RNP-70k</td>
<td>Leucopenia</td>
<td>3.4</td>
<td>1.4 to 8.0</td>
</tr>
<tr>
<td>Ribosomal P</td>
<td>Leucopenia</td>
<td>3.4</td>
<td>1.4 to 8.0</td>
</tr>
<tr>
<td>At least 2 RNP reactivities</td>
<td>Leucopenia</td>
<td>3.2</td>
<td>1.5 to 6.6</td>
</tr>
<tr>
<td>At least 1 antibody of cluster 2</td>
<td>Xerostomia</td>
<td>3.2</td>
<td>1.5 to 6.8</td>
</tr>
<tr>
<td>Ro52 or Ro60</td>
<td>Xerostomia</td>
<td>3.1</td>
<td>1.5 to 6.4</td>
</tr>
<tr>
<td>Ro60</td>
<td>Xerostomia</td>
<td>3.1</td>
<td>1.5 to 6.4</td>
</tr>
<tr>
<td>dsDNA</td>
<td>Cellular casts</td>
<td>3.1</td>
<td>1.4 to 7.1</td>
</tr>
<tr>
<td>At least 2 RNP reactivities</td>
<td>Arthritis</td>
<td>3.1</td>
<td>1.4 to 6.6</td>
</tr>
<tr>
<td>Ro52 or Ro60</td>
<td>Xerostomia</td>
<td>2.9</td>
<td>1.3 to 6.1</td>
</tr>
<tr>
<td>At least 1 antibody of cluster 2</td>
<td>Xerostomia</td>
<td>2.7</td>
<td>1.3 to 5.8</td>
</tr>
<tr>
<td>At least 1 antibody of cluster 2</td>
<td>Xerostomia</td>
<td>2.7</td>
<td>1.3 to 5.8</td>
</tr>
<tr>
<td>RNP-C</td>
<td>Raynaud’s phenomenon</td>
<td>2.5</td>
<td>1.3 to 4.9</td>
</tr>
<tr>
<td>At least 1 antibody of cluster 1</td>
<td>Butterfly rash</td>
<td>2.4</td>
<td>1.2 to 4.5</td>
</tr>
<tr>
<td>Histones</td>
<td>Arthritis</td>
<td>2.3</td>
<td>1.2 to 4.4</td>
</tr>
<tr>
<td>RNP-70k</td>
<td>Fatigue</td>
<td>1.2</td>
<td>1.1 to 1.3</td>
</tr>
<tr>
<td>dsDNA</td>
<td>Photosensitivity</td>
<td>0.4</td>
<td>0.2 to 0.7</td>
</tr>
<tr>
<td>RNP-A</td>
<td>Cellular casts</td>
<td>0.3</td>
<td>1.1 to 2.7</td>
</tr>
<tr>
<td>RNP-C</td>
<td>Cellular casts</td>
<td>0.3</td>
<td>1.1 to 2.7</td>
</tr>
</tbody>
</table>

OR, odds ratio; 95% CI, 95% confidence interval.

*Inverse associations (OR < 1.0).
antibodies and lupus nephropathy.1–4 We found significant associations with the presence of cellular casts in the urine during the past year. Furthermore, we found an inverse association with photosensitivity ever, as described by Podrebarac et al.14

In conclusion, using a sensitive and specific multiparameter assay for identifying antinuclear reactivities, we found clusters of antibodies and could confirm previously reported associations of antibodies with clinical symptoms of SLE. Most striking are the associations of anti-RNP antibodies with Raynaud's phenomenon, of anti-SSA and anti-SSB antibodies with sicca symptoms, and of antiribosomal P antibodies with haematological symptoms. We also found several new associations meriting further study. In our view, the most important finding is the lower occurrence of cellular casts in patients with antibodies to the individual RNP-A and RNP-C subparticles.

ACKNOWLEDGEMENTS
I Hoffman is supported by a research grant from the “Bijzonder Onderzoeksfonds”, Ghent University.

We thank Hans Pottel and Annelies De Brauwer for their excellent statistical advice, and Caroline Dobbels for her technical assistance.

Authors’ affiliations
I E A Hoffman, I Peene, E M Veys, F De Keyser, Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
L Meheus, K De Bosschere, F Hulstaert, Innogenetics NV, Zwijnaarde, Belgium
T W J Huizinga, Department of Rheumatology, Leids Universitair Medisch Centrum, Leiden, The Netherlands
L Cebecauer, Research Institute for Rheumatic Diseases, Piestany, Slovakia
D Isenberg, Centre For Rheumatology, University College London, London, UK

Correspondence to: Dr I Hoffman, Department of Rheumatology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium; Ilse.Hoffman@UGent.be

Accepted 17 October 2003

REFERENCES
9 Peene I, Meheus L, Veys EM, De Keyser F. Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated diseases differs according to the detailed serotype. Ann Rheum Dis 2002;61:1090–4.

www.annrheumdis.com